drugset / Trial / NCT06217887

Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients

NCT06217887

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, open label, parallel,4-month study to explore and evaluate the therapeutic effects of polyethylene glycol loxenatide on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with normal cognitive status or MCI.

Timeline

Start
2020-05-10
Primary completion
2024-02
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gliclazide Small molecule 30 mg
Subject Loxenatide Unknown 0.2 mg